IRLA · IRulya Therapeutics Inc. · Insider Trading

100% of the shares subject to this stock option will vest on the one-year anniversary of the grant date.

100% of the shares subject to this stock option will vest on the one-year anniversary of the grant date.

Received in exchange for stock options to acquire an aggregate of 100,000 shares of Orphai common stock with an exercise price of $0.06 per share pursuant to the Merger Agreement.

Immediately exercisable.

Received in exchange for stock options to acquire an aggregate of 9,859,148 shares of Orphai common stock with an exercise price of $0.58 per share pursuant to the Merger Agreement.

Immediately exercisable.

Received in exchange for stock options to acquire an aggregate of 2,985,015 shares of Orphai common stock with an exercise price of $0.06 per share pursuant to the Merger Agreement.

Immediately exercisable.

Received in exchange for stock options to acquire an aggregate of 192,668 shares of Orphai common stock with an exercise price of $0.06 per share pursuant to the Merger Agreement.

Immediately exercisable.

Received in exchange for a stock option to acquire 50,000 shares of Orphai Therapeutics, LLC ("Orphai") common stock with an exercise price of $0.06 per share pursuant to an Agreement and Plan of Merger, dated May 17, 2026 (the "Merger Agreement"), by and among the Issuer, Phoenix Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of the Issuer ("First Merger Sub"), Phoenix Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of the Issuer ("Second Merger Sub"), Orphai Holdings Therapeutics, Inc., a Delaware corporation ("HoldCo") and Orphai.

Immediately exercisable.

Received in exchange for stock options to acquire an aggregate of 522,124 shares of Orphai common stock with an exercise price of $0.06 per share pursuant to the Merger Agreement.

Immediately exercisable.

Received in exchange for stock options to acquire an aggregate of 9,859,148 shares of Orphai common stock with an exercise price of $0.58 per share pursuant to the Merger Agreement.

Beginning May 21, 2026, the shares subject to the option vest in a series of thirty-six (36) successive equal monthly installments, subject to the Reporting Person's Continued Service (as defined in the Orphai's 2026 Stock Incentive Plan) wih the Issuer as of each such vesting date.

Received in exchange for stock options to acquire an aggregate of 330,000 shares of Orphai common stock with an exercise price of $0.06 per share pursuant to the Merger Agreement.

Immediately exercisable.

Received in exchange for stock options to acquire an aggregate of 180,000 shares of Orphai common stock with an exercise price of $0.06 per share pursuant to the Merger Agreement.

Immediately exercisable.

The shares subject to this option shall vest in equal monthly installments, at a rate of 1/48th of the total number of shares on each monthly anniversary of the vesting with 1/48th vesting on the date of grant and the remaining options vesting on the 1st day of each subsequent month, such that the total number of shares shall be fully vested on December 1, 2029.

The shares subject to this option shall vest in equal monthly installments, at a rate of 1/48th of the total number of shares on each monthly anniversary of the vesting with 1/48th vesting on the date of grant and the remaining options vesting on the 1st day of each subsequent month, such that the total number of shares shall be fully vested on December 1, 2029.

The shares subject to this option shall vest in equal monthly installments, at a rate of 1/48th of the total number of shares on each monthly anniversary of the vesting with 1/48th vesting on the date of grant and the remaining options vesting on the 1st day of each subsequent month, such that the total number of shares shall be fully vested on December 1, 2029.

The shares subject to the option shall vest in equal quarterly installments over a one year-period. The Reporting Person elected to receive the stock options in lieu of the annual director cash retainer for 2026 provided for under the Issuer's Outside Director Compensation Policy.

The shares subject to the option shall vest in equal quarterly installments over a one year-period. The Reporting Person elected to receive the stock options in lieu of the annual director cash retainer for 2026 provided for under the Issuer's Outside Director Compensation Policy.

The shares subject to the option shall vest in equal quarterly installments over a one year-period. The Reporting Person elected to receive the stock options in lieu of the annual director cash retainer for 2026 provided for under the Issuer's Outside Director Compensation Policy.

The shares subject to the option shall vest in equal quarterly installments over a one year-period. The Reporting Person elected to receive the stock options in lieu of the annual director cash retainer for 2026 provided for under the Issuer's Outside Director Compensation Policy.

The sale price reported above is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.45 to $3.56, inclusive. The reporting person undertakes to provide to Quince Therapeutics, Inc., any security holder of Quince Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Represents grant of 103,500 employee stock options on May 19, 2022, which vest over a four-year period, with 25% of the shares subject to the option vesting on the first anniversary of the vesting commencement date and the remainder vesting in 36 equal monthly installments over the following three years.

Represents grant of 225,000 employee stock options on February 2, 2023, which vest in equal monthly installments at a rate of 1/48th of the total number of shares on each monthly anniversary of the vesting commencement date of January 1, 2023, with full vesting on the fourth annual anniversary of the vesting commencement date.

The shares subject to the option shall vest 100% on the one-year anniversary of the grant date. The Reporting Person elected to receive the stock options in lieu of the annual director cash retainer for 2025 provided for under the issuer's Outside Director Compensation Policy.

The shares subject to the option shall vest 100% on the one-year anniversary of the grant date. The Reporting Person elected to receive the stock options in lieu of the annual director cash retainer for 2025 provided for under the issuer's Outside Director Compensation Policy.

The shares subject to the option shall vest 100% on the one-year anniversary of the grant date. The Reporting Person elected to receive the stock options in lieu of the annual director cash retainer for 2025 provided for under the issuer's Outside Director Compensation Policy.

The shares subject to the option shall vest 100% on the one-year anniversary of the grant date. The Reporting Person elected to receive the stock options in lieu of the annual director cash retainer for 2025 provided for under the issuer's Outside Director Compensation Policy.

The shares subject to the option shall vest 100% on the one-year anniversary of the grant date. The Reporting Person elected to receive the stock options in lieu of the annual director cash retainer for 2025 provided for under the issuer's Outside Director Compensation Policy.

The shares subject to the option shall vest 100% on the one-year anniversary of the grant date. The Reporting Person elected to receive the stock options in lieu of the annual director cash retainer for 2025 provided for under the issuer's Outside Director Compensation Policy.

The shares subject to the option shall vest 100% on the one-year anniversary of the grant date. The Reporting Person elected to receive the stock options in lieu of the annual director cash retainer for 2025 provided for under the issuer's Outside Director Compensation Policy.

The shares subject to this option shall vest in equal monthly installments, at a rate of 1/48th of the total number of shares on each monthly anniversary of the vesting commencement date of January 1, 2025, such that the total number of shares shall be fully vested on the four-year anniversary of the vesting commencement date.

The shares subject to this option shall vest in equal monthly installments, at a rate of 1/48th of the total number of shares on each monthly anniversary of the vesting commencement date of January 1, 2025, such that the total number of shares shall be fully vested on the four-year anniversary of the vesting commencement date.

The shares subject to this option shall vest in equal monthly installments, at a rate of 1/48th of the total number of shares on each monthly anniversary of the vesting commencement date of January 1, 2025, such that the total number of shares shall be fully vested on the four-year anniversary of the vesting commencement date.

The shares subject to the option shall vest in equal quarterly installments over a one year-period. The Reporting Person elected to receive the stock options in lieu of the annual director cash retainer for 2025 provided for under the Issuer's Outside Director Compensation Policy.

The shares subject to the option shall vest in equal quarterly installments over a one year-period. The Reporting Person elected to receive the stock options in lieu of the annual director cash retainer for 2025 provided for under the Issuer's Outside Director Compensation Policy.

The shares subject to the option shall vest in equal quarterly installments over a one year-period. The Reporting Person elected to receive the stock options in lieu of the annual director cash retainer for 2025 provided for under the Issuer's Outside Director Compensation Policy.

The shares subject to the option shall vest in equal quarterly installments over a one year-period. The Reporting Person elected to receive the stock options in lieu of the annual director cash retainer for 2025 provided for under the Issuer's Outside Director Compensation Policy.

In connection with the Stock Purchase Agreement between the Issuer and EryDel Italy Inc.announced in the Issuer's 8-k filed with the Securities and Exchange Commission on July 24, 2023 (the "Acquisition"), 10% of the shares of common stock of the Issuer issued to the Reporting Person in connection with the Acquisition were held back for one (1) year following closing and released to the Reporting Person on October 23, 2024.

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.67 to $0.72, inclusive.

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.66 to $0.71, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4.